Bibliographic Details
| Title: |
What have we learned from the REPRIEVE trial and where do we go from here? |
| Authors: |
Grinspoon, Steven K.1 sgrinspoon@mgh.harvard.edu, Lu, Michael T.2, Zanni, Markella V.1, Diggs, Marissa R.1, Chu, Sarah M.1, Ribaudo, Heather J.3, Douglas, Pamela S.4 |
| Source: |
HIV Medicine. Dec2024, Vol. 25 Issue 12, p1283-1288. 6p. |
| Subject Terms: |
*ANTILIPEMIC agents, *HIV-positive persons, *MAJOR adverse cardiovascular events, *CARDIOVASCULAR diseases risk factors, *GLOBAL burden of disease, *LDL cholesterol, *STATINS (Cardiovascular agents), *AMYLOID plaque, *COLLAGEN |
| Abstract: |
An editorial focuses on the REPRIEVE trial, which tested pitavastatin for preventing cardiovascular events in people with HIV (Human Immunodeficiency Virus). It shows that statin therapy significantly reduces CVD (Cardiovascular Disease) risk, particularly in those with low-to-moderate predicted risk, addressing both traditional and HIV-related factors. |
| Database: |
Academic Search Complete |
